Clinical Trial Update: A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) [Phase 2]

View source ↗

Summary

Phase 2 long-term follow-up study of duvelisib (IPI-145) in participants with hematologic malignancies; status completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: SecuraBio | Conditions: Hematologic Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2023-02-21